Quantcast

Adequan

AQHA Corporate Partner Adequan provides an update on the supply shortage.

Adequan
September 17, 2013

Adequan

AQHA Corporate Partner Adequan provides an update on the supply shortage.

Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturers of Adequan IM, Adequan IA and Adequan Canine announced that a shipment of Adequan (polysulfated glycosaminoglycan) IM was released to the market last week and was received by veterinarians beginning Friday, September 13.

Adequan product supply remains limited and the initial shipments will not fully satisfy market demand. Luitpold made significant investments in upgrading its manufacturing facilities earlier this year. The time spent making these upgrades impacted the company’s ability to keep up with demand. The company is working diligently to release additional product to the market and will provide updates as they become available. Adequan users are encouraged to continue to work with their veterinarians to obtain the drug and discuss the most appropriate treatment regimen for your animals.

Luitpold has established a dedicated webpage on www.adequan.com where concerned parties can register to receive future communications and updates on this matter. Adequan users may also contact the company’s Customer Service Department toll-free at (800) 458-0163.

Adequan IM and IA are the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses. Adequan Canine is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.